JTE-607 structure
|
Common Name | JTE-607 | ||
---|---|---|---|---|
CAS Number | 188791-09-5 | Molecular Weight | 597.36 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C25H33Cl4N3O5 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of JTE-607JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively[1]. Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607[2]. |
Name | ethyl (2S)-2-[[3,5-dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]amino]-3-phenylpropanoate,dihydrochloride |
---|---|
Synonym | More Synonyms |
Description | JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively[1]. Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607[2]. |
---|---|
Related Catalog | |
In Vitro | JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively. The inhibitory effects of JTE-607 are also seen in mRNA expression of those cytokines[1]. JTE-607 inhibits inflammatory cytokine production from LPS-stimulated human PBMCs with an IC50 of approximately 10 nM[1]. JTE607 inhibits LPS-stimulated IL-8 production from monkey and rabbit PBMCs, and TNF-α production from mouse and rat PBMCs with IC50s of 59, 780, 1600 and 19000 nM, respectively[1]. JTE607 also suppresses other cytokines, granulocyte-macrophage colony stimulating factor and IL-1RA with IC50s of 2.4±0.8 and 5.4±0.4 nM, respectively[1]. JTE-607 inhibits cytokine production in monkey, rabbit, mouse and rat with IC50s of 59±26, 780±120, 1600±650 and 19000±3200 nM, respectively[1]. RT-PCR[1] Cell Line: human peripheral blood mononuclear cells (PBMCs) Concentration: 100 nM Incubation Time: 20 hours Result: Reduced the increase in the level of mRNAs of TNF-α, IL-1b, IL-6 and IL-8. |
In Vivo | JTE-607 (0.3-10 mg/kg, i.v.) shows dose dependent inhibition of mortality after LPS challenge in C. parvum sensitized mice in accordance with a decrease of plasma TNF-α[1]. Animal Model: Male C57BL/6 mice (5 to 6 weeks old) are sensitized by injecting Corynebacterium parvum[1] Dosage: 0.3, 1, 3, 10 mg/kg Administration: Administered intravenously 10 min before the LPS challenge. Result: Showed dose dependent inhibition of the mortality at 0.3 to 10 mg/kg and significant effect at 3 and 10 mg/kg. |
References |
Molecular Formula | C25H33Cl4N3O5 |
---|---|
Molecular Weight | 597.36 |
Exact Mass | 595.11700 |
PSA | 94.83000 |
LogP | 5.28400 |
unii-2b68h6bwcx |
jte-607 |